ASH 2020: Lilly's LOXO-305 shows a 62% mitigation rate in relapse-difficult CLL/SLL

Lilly recently released the latest results from the Phase I/II Clinical Trials (BRUIN Study), which evaluated the effectiveness of the non-co-priced BTK inhibitor LOXO-305 in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
results presented at the American Society of Hematology (ASH) meeting showed that of the 121 patients treated with BTK, the total remission rate (ORR) was 62 percent after six months of middle follow-up and 84 percent of patients who followed for 10 months or more.
Lilly said the "deepening response" over time showed that the overall efficacy of loXO-305 "will continue to be enhanced through further follow-up."
updated BRUIN data "reveals the incredible safety and efficacy of LOXO-305 in patients with a large number of treated relapses and SLL."
BRUIN study is evaluating LOXO-305 as a single-drug treatment for patients with recurring difficult-to-treat CLL, SLL, or non-Hodgkin's lymphoma who have previously received at least two treatments and have progressed or are not resistant to standard treatment.
end point of phase II dose extension in this study was ORR, and the secondary endpoint included reaction duration and overall lifetime.
27 September, a total of 323 patients, including 170 CLL/SLL participants, participated in the study.
Lilly noted that 86 percent of the CLL/SLL queues had previously received BTK inhibitors, 90 percent had previously received anti-CD20 antibodies, 82 percent had previously received chemotherapy, 34 percent had previously received AbbVie's Venetoclax, 21 percent had previously received PI3K inhibitors, 6 percent had previously received CAR-T treatment and 2 percent had previously received the same allogeneic stem cell transplant.
。